•Over 30 years of clinical pharmacology experience with success in the development of large molecule (therapeutic proteins) and small molecule oncology drugs in early and late stages of clinical development. Effective mentor of junior scientists and students. •Significant leadership and contributions to the development of approved oncology molecules: trastuzumab (Herceptin IV and SC), bevacizumab (Avastin), pertuzumab (Perjeta), ado-trastuzumab emtansine (Kadcyla), vismodegib (Erivedge), cobimetinib ((GDC-0973, XL518) and erlotinib (Tarceva). •Experience in US, European and Global regulatory filings of marketing applications (NDAs, BLAs) and associated interactions with Health Authorities. •Proficiency in team leadership and strategic scientific decision-making that enhances scientific and commercial development with a strong patient/practitioner-oriented focus. •Accomplished scientific author/writer in the area of clinical pharmacology and oncology for peer-reviewed publications, clinical study protocols, regulatory documents, and health authority responses. •Strong capability for effective communications and team interactions across disciplines. •Significant contributions to the programs of professional and non-profit organizations.